師資
張路，南方科技大學生物醫(yī)學工程系副教授，博士生導師，國家重點研發(fā)首席科學家，海外優(yōu)青。2016年博士畢業(yè)于中山大學化學與化學工程學院（師從帥心濤教授），同年赴美加入加州大學戴維斯分校醫(yī)學中心開展博士后研究（師從組合化學及分子醫(yī)學領域權威專家Kit S. Lam講席教授）。2021年8月回國加入南方科技大學生物醫(yī)學工程系，組建納米生物醫(yī)學 (Nano Biomedicine，NBM) 課題組，任課題組組長（獨立PI）。
課題組科研圍繞“生物醫(yī)用納米材料活體仿生組裝、結構調控與癌癥診療的關系”進行系統(tǒng)研究，涉及化學、材料、生物、醫(yī)學和工程交叉學科，研究內容主要包括納米藥物精準遞送、活體原位仿生自組裝、納米藥劑臨床轉化應用等。
目前主持國家重點研發(fā)計劃“合成生物學”重點專項（2023）、國家自然科學基金優(yōu)秀青年科學基金項目（海外）、國家自然科學基金面上項目（2022）、廣東省基礎與應用基礎研究基金自然科學基金面上項目（2024）、深圳市自然科學基金面上項目（2022）等。
以通訊及第一作者在Nature Nanotechnology、Nature Communications、Nano Letters、ACS Nano、Biomaterials、Advanced Functional Materials、Hepatology、Theranostics等高水平期刊上發(fā)表多篇SCI論文，研發(fā)的納米技術及藥劑已獲多項國際及國內專利授權，并被FDA批準正在美國開展多項納米藥劑臨床轉化實驗。
工作 & 教育背景
2022.12-至今 副教授（PI） 南方科技大學 生物醫(yī)學工程系
2021.08-2022.12 助理教授（PI） 南方科技大學 生物醫(yī)學工程系
2016.09-2021.07 博士后, 美國加州大學戴維斯分校，醫(yī)學中心，生物化學與分子醫(yī)學系
導師：Kit S Lam教授 (組合化學和分子醫(yī)學領域權威專家)
2011.09-2016.06 博士 (碩博連讀)，中山大學，化學與化學工程學院
導師：帥心濤教授 (國家杰出青年科學基金獲得者)
研究方向
針對臨床癌癥精準成像診斷和高效治療面臨的難題開展工作，圍繞“生物醫(yī)用納米材料活體仿生組裝、結構調控與癌癥診療的關系”科學問題進行系統(tǒng)研究，牢牢扎根在化學、材料、生物、醫(yī)學和工程交叉學科研究的前沿，選用生物相容性好、人體安全性高的多肽或聚氨基酸為基礎生物材料，研究內容聚焦三個方面：
1） 納米藥物精準遞送：建立精準調控納米結構尺寸的新方法，提升納米藥物體內穩(wěn)定性、靈敏性，提出AIE/ACQ熒光比率新策略，實現(xiàn)納米結構組裝與解離動態(tài)監(jiān)測，解決如何將納米藥更精準、更高效、更靈敏地送到癌癥病灶部位；
2） 活體原位仿生自組裝：在動物活體環(huán)境下，發(fā)展膜蛋白特異性的β折疊新多肽材料，提出納米材料纖維化組裝進行無藥物治療新策略，建立重塑活體細胞表面的新型生物技術平臺，在癌癥病灶部位，基于納米材料原位自組裝形貌轉變，提升納米藥物及材料的體內生物利用度；
3） 納米藥劑臨床轉化應用：推進納米藥劑的臨床轉化應用研究，開展基礎科研與臨床科學結合的系統(tǒng)研究。
代表性成果
文章
1) Lu Zhang#, Di Jing#, Nian Jiang, Tatu Rojalin, Christopher M. Baehr, Dalin Zhang, Wenwu Xiao, Yi Wu, Zhaoqing Cong, Jian Jian Li, Yuanpei Li, Lei Wang*, Kit S. Lam*. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nature Nanotechnology 2020, 15(2), 145-153. (IF: 40.523)
2) Chunping Mao, Fuan Deng, Wanning Zhu, Leiming Xie, Yijun Wang, Guoyin Li, Xingke Huang, Jiahui Wang, Yue Song, Ping Zeng, Zhenpeng He, Jingnan Guo, Yao Suo, Yujing Liu, Zhuo Chen, Mingxi Yao, Lu Zhang*, Jun Shen*. In Situ Editing of Tumour Cell Membranes Induces Aggregation and Capture of PD-L1 Membrane Proteins for Enhanced Cancer Immunotherapy. Nature Communications 2024, 15, 9723. (IF: 14.7)
3) Yichi Chen, Yijun Wang, Ruotian Zhang, Fengyi Wang, Xin Lin, Tong Wang, Wenyuan Zhang, Fuan Deng, Bolin Wu, Haitao Shang, Wen Cheng*, Lu Zhang*. In Situ Transformable Fibrillar Clusters Disrupt Intracellular Copper Metabolic Homeostasis by Comprehensive Blockage of Cuprous Ions Efflux. Small 2024, 2406802. (IF: 13.0)
4) Wenyuan Zhang, Liejing Lu, Zheng Zhu, Fuan Deng, Wenchang Zhang, Fengyi Wang, Ping Zeng, Haonan Shi, Tong Wang, Yichi Chen, Yue Song, Yiping Liu, Tianze Kang, Kai Li, Jie Mao, Zhengwei Liu*, Lu Zhang*. A Manganese-Based Nanodriver Coordinates Tumor Prevention and Suppression through STING Activation in Glioblastoma. Adavnced Hralthcare Materials 2024, 202400421. (IF: 10.0)
5) Wenyuan Zhang, Jianrui Zhang, Yijun Wang, Senyao Wang, Yitian Wu, Wenchang Zhang, Minghui Wu, Li Wang, Guoheng Xu, Fuan Deng, Wenchao Liu, Zhengwei Liu*, Lu Chen*, Kai Xiao*, Lu Zhang*. In Vitro Detection of S100B and Severity Evaluation of Traumatic Brain Injury Based on Biomimetic Peptide-Modified Nanochannels. Small 2023, 2306809. (IF: 13.3)
6) Di Jing, Nian Jiang, Fengyi Wang, Chunping Mao, Shujun Han, Pui Yan Ho, Wenwu Xiao, Yuanpei Li, Jian-Jian Li, Lu Zhang*(co-corresponding), Kit S Lam*. Nanoradiosensitizer with good tissue penetration and enhances oral cancer radiotherapeutic effect. Biomaterials 2022, 289, 121769. (IF: 15.304)
7) Lu Zhang*(co-corresponding), Ruonan Bo, Yi Wu, Longmeng Li, Zheng Zhu, Ai-Hong Ma, Wenwu Xiao, Yanyu Huang, Tatu Rojalin, Xingbin Yin, Chunping Mao, Fengyi Wang, Yongheng Wang, Hongyong Zhang, Kelmen E. Low, Kiana Lee, Yousif Ajena, Di Jing, Dalin Zhang, Christopher M. Baehr, Ruiwu Liu, Lei Wang*, Yuanpei Li*, Kit S. Lam*. A programmable bispecific nano-immuno-engager captures T cells and reprograms tumor microenvironment. Nano Letters 2022, 22 (17), 6866-6876. (IF: 12.262)
8) Zhiqin Zhang, Kaixin Wang, Manting Liu, Panxiang Hu, Yuchen Xu, Dongge Yin, Yuchang Yang, Xiaoxv Dong, Changhai Qu, Lu Zhang* (co-corresponding), Jian Ni*, Xingbin Yin*. Phototherapeutic effect of transformable peptides containing pheophorbide a on colorectal cancer. Drug Delivery 2022, 29(1), 1608-1619. (IF: 6.819)
9) Lu Zhang, Yi Wu, Xingbin Yin, Zheng Zhu, Tatu Rojalin, Wenwu Xiao, Dalin Zhang, Yanyu Huang, Longmeng Li, Christopher M. Baehr, Xingjian Yu, Yousif Ajena, Yuanpei Li, Lei Wang* and Kit S. Lam*. Tumor Receptor-Mediated In Vivo Modulation of the Morphology, Phototherapeutic Properties, and Pharmacokinetics of Smart Nanomaterials. ACS Nano 2021, 15(1), 468-479. (IF: 18.027)
10) Hao Wu#, Lu Zhang#(co-first), Jinfan Yang, Ruonan Bo, Hongxu Du, Kai Lin, Dalin Zhang, Mythili Ramachandran, Yingbin Shen, Yangxi Xu, Xiangdong Xue, Zhao Ma, Aaron Raymond Lindstrom, Randy Carney, Tzu-Yin Lin, Yuanpei Li*. Rotatable Aggregation-Induced-Emission/Aggregation Caused-Quenching Ratio Strategy for Real-Time Tracking Nanoparticle Dynamics. Advanced Functional Materials 2020, 30(15), 1910348. (IF: 19.924)
11) Lu Zhang#, Hao Wu#, Yuanpei Li*, Kit S. Lam*. Nanoengineered Biomaterials for Advanced Drug Delivery (11th chapter) Reversible Cross-Linked Polymeric Micelles for Drug Delivery. Elsevier, 2020, 243-260. (Academic Treatise)
12) Mengru Cai, Liuying Qin, Longtai You, Yu Yao, Huimin Wu, Zhiqin Zhang, Lu Zhang* (co-corresponding), Xingbin Yin*, Jian Ni*. Functionalization of MOF-5 with Mono-Substituents: Effects on Drug Delivery Behavior. RSC Advances 2020, 10(60), 36862-36872. (IF: 4.036)
13) Lu Zhang, Yanyu Huang, Aaron Raymond Lindstrom, Tzu-Yin Lin, Kit S Lam, Yuanpei Li*. Peptide-based materials for cancer immunotherapy. Theranostics 2019, 9(25), 7807-7825. (IF: 11.6)
14) Lu Zhang#, Tinghui Yin#, Bo Li, Rongqin Zheng*, Chen Qiu, Kit S. Lam*, Qi Zhang, Xintao Shuai*. Size-Modulable Nanoprobe for High-Performance Ultrasound Imaging and Drug Delivery against Cancer. ACS Nano 2018, 12(4), 3449-3460. (IF: 18.027)
15) Lu Zhang#, Di Jing#, Lei Wang, Yuan Sun, Jian Jian Li, Brianna Hill, Fan Yang, Yuanpei Li*, Kit S. Lam*. Unique Photochemo-Immuno-Nanoplatform against Orthotopic Xenograft Oral Cancer and Metastatic Syngeneic Breast Cancer. Nano Letters 2018, 18(11), 7092-7103. (IF: 12.262)
16) Hao Wu#, Lu Zhang#(co-first), Yuanpei Li*; Kit S. Lam*; Stimuli-Responsive Materials in Theranostics. Royal Society of Chemistry, 2018. (Academic Treatise)
17) Yu Guo#, Jing Wang#, Lu Zhang#(co-first), Shunli Shen#, Ruomi Guo, Yang Yang*, Wenjie Chen, Yiru Wang, Guihua Chen*, Xintao Shuai*. Theranostical Nanosystem-Mediated Identification of An Oncogene and Highly Effective Therapy in Hepatocellular Carcinoma. Hepatology 2016, 63(4), 1240-1255. (IF: 17.298)
18) Lu Zhang#, Hong Xiao#, Jingguo Li, Du Cheng*, Xintao Shuai*. Co-delivery of doxorubicin and arsenite with reduction and pH dual-sensitive vesicle for synergistic cancer therapy. Nanoscale 2016, 8(25), 12608-12617. (IF: 8.307)
19) Pei-Pei Yang#, Yi-Jing Li#, Yan Cao#, Lu Zhang, Jia-Qi Wang, Zi-Wei Lai, Kuo Zhang, Diedra Shorty, Wenwu Xiao, Hui Cao, Lei Wang*, Hao Wang*, Ruiwu Liu*, Kit S. Lam*. Rapid discovery of self-assembling peptides with one-bead one-compound peptide library. Nature Communications 2021, 12, 4494. (IF: 17.694)
20) Christopher M. Baehr, Lu Zhang, Yi Wu, Andras Domokos, Wenwu Xiao, Lei Wang, Kit S.Lam*. Transformable amyloid-beta mimetic peptide amphiphiles for lysosomal disruption in non-small cell lung cancer. Biomaterials 2021, 277, 121078. (IF: 15.304)
21) Zhaoqing Cong, Lu Zhang, Si-Qi Ma, Kit S.Lam, Fei-Fei Yang*, YongHong Liao*. Size-Transformable Hyaluronan Stacked Self-Assembling Peptide Nanoparticles for Improved Transcellular Tumor Penetration and Photo-Chemo Combination Therapy. ACS Nano 2020, 14(2), 1958-1970. (IF: 18.027)
22) Christopher M. Baehr，Lu Zhang, Kit S. Lam*. Abstract 1740: Transformable amyloid-beta mimetic peptide amphiphiles for lysosomal disruption and cisplatin sensitization in non-small cell lung cancer. Cancer Research, 2020. (IF: 11.2)
23) Hong Xiao, Jin He, Xiaoxia Li, Bo Li, Lu Zhang, Yong Wang*, Du Cheng, Xintao Shuai*. Polymeric Nanovesicles as Simultaneous Delivery Platforms with Doxorubicin Conjugation and Elacridar Encapsulation for Enhanced Treatment of Multidrug-Resistant Breast Cancer. Journal of Materials Chemistry B 2018, 6(45), 7521-7529. (IF: 7.571)
24) Yi Huang, Xiaoxia Li, Lu Zhang, Xiaoyan Chen, Chengbo Liu, Jingqin Chen, Yong Wanga*, XinTao Shuai. Multifunctional Nanoplatform Based on pH-responsive Micelle Coated with Discontinuous Gold Shell for Cancer Photothermo-chemotherapy and Photoacoustic Tomography. Chinese Journal of Polymer Science, 2018, 36, 1139-1149. (IF: 3.815)
25) Jingguo Li, Lu Zhang, Yujie Lin, Hong Xiao, Mingxiang Zuo, Du Cheng, Xintao Shuai*. A pH-Sensitive Prodrug Micelle Self-Assembled from MultiDoxorubicin-Tailed Polyethylene Glycol for Cancer Therapy. RSC Advances. 2016, 6(11), 9160-9163. (IF: 4.036)
26) Faming Gong, Zuoquan Zhang, Xiaodong Chen, Lu Zhang, Xingsu Yu, Qihua Yang, Xintao Shuai, Biling Liang*, Du Cheng*. A dual ligand targeted nanoprobe with high MRI sensitivity for diagnosis of breast cancer[J]. Chinese Journal of Polymer Science, 2014, 32(3), 321-332. (IF: 3.815)
專利
1) Kit S. Lam, Lu Zhang; Cyanine-based telodendrimers and uses for treating cancer, 2020-5-3, WIPO, PCT/US2019/049080
2) Kit S. Lam, Lu Zhang; Smart peptides and transformable nanoparticles for cancer immunotherapy, 2021-2-18, WIPO, PCT/US2020/046495
3) 羅智；李金娜·哈比布利納；張宇航；張路；姚明曦；李喆；一種液態(tài)金屬墨水及其制備方法和應用，2024-07-17，2024109674906
4) 魯敬雄；張路；曹玲燕；杜詠軒；一種DNA水凝膠及其制備方法，2024-08-23，2024111689897
5) 魯敬雄；張路；曹玲燕；杜詠軒；一種用于核酸檢測的 DNA 水凝膠傳感器及其制備方法，2024-08-23，202411169049X
6) 張路；沈君；毛椿平；一種用于結合PD-L1的多肽納米材料及其制備方法與應用，2023-10-13，CN202310758599.4
7) 帥心濤，張路，邱晨，黃毅，左明祥，程度；一種pH與溫度雙重敏感性的納米囊泡及其制備方法和應用，2016-07-12，CN201610548026.9
臨床轉化應用
已開發(fā)多種 GMP 及 GLP 級別的樹枝狀大分子聚合物包載化療藥和免疫藥物的納米藥劑, 化療藥 (Doxorubicin, Paclitaxel 等)，免疫藥物(Resiquimod, Imiquimod等)；并在美國獲準應用于鼠、兔、貓和狗等動物的膀胱癌、口腔癌、卵巢癌和乳腺癌等模型的臨床前研究。
主持科研基金項目
1) 廣東省基礎與應用基礎研究基金自然科學基金面上項目（2024）
2) 國家重點研發(fā)計劃“合成生物學”重點專項（2023)
3) 國家自然科學基金優(yōu)秀青年科學基金項目（海外2022）
4) 國家自然科學基金面上項目（2022）
5) 深圳市自然科學基金面上項目（2022）
曾主持或參與項目
1) National Cancer Institute (NCI), 1R01CA247685-01, HER2 targeting transformable nanotherapeutic platform against HER2+ cancers, 2020.02-2025.01, $572,096 (Each year).
2) Department of Defense (DOD), W81XWH-19-1-0204, Delivery of targeting nano-photo-imiquimod to greatly enhance check point blockade immunotherapy of patients with advanced bladder cancer, 2019.07-2023.06, $1,037,215 (Each year).
3) Department of Defense (DOD), W81XWH-19-1-0159, Novel nano-photo-immunotherapy against ovarian cancer, 2019.06-2022.06, $234,000 (Each year).
4) National Cancer Institute (NCI), 5R01CA115483-13, Therapeutic targeting agents for ovarian cancer, 2015.01-2021.04, $334,535 (Each year).
5) National Institute of Biomedical Imaging and Bioengineering (NIBIB), 2R01EB012569-09, Targeting nanotherapeutics against murine and feline oral cancer, 2010.12-2021.05, $518,074 (Each year).